Clinical Trials Logo

Healthy Male Subjects clinical trials

View clinical trials related to Healthy Male Subjects.

Filter by:

NCT ID: NCT06111196 Active, not recruiting - Clinical trials for Healthy Male Subjects

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

Start date: November 5, 2023
Phase: Phase 1
Study type: Interventional

to Compare the Pharmacokinetics and Safety of BAT3306 versus KEYTRUDA® Administered in Healthy Male Subjects

NCT ID: NCT06087978 Completed - Clinical trials for Healthy Male Subjects

Study of RPT193 in Healthy Adult Male Subjects

Start date: July 5, 2023
Phase: Phase 1
Study type: Interventional

Phase 1, open-label, absorption, metabolism, excretion, and mass balance study.

NCT ID: NCT05998304 Completed - Clinical trials for Healthy Male Subjects

ADME Study of [14C] Yiqibuvir in Healthy Male Subjects

Start date: August 7, 2023
Phase: Phase 1
Study type: Interventional

This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of [14C] Yiqibuvir.

NCT ID: NCT05888207 Completed - Clinical trials for Healthy Male Subjects

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

Start date: June 2, 2023
Phase: Phase 1
Study type: Interventional

This study will assess the effects of strong CYP1A2 (Cytochrome P450 1A2) inhibitor (fluvoxamine) on savolitinib exposure in healthy male subjects, performed at a single clinical unit.

NCT ID: NCT05792917 Completed - Clinical trials for Healthy Male Subjects

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Start date: March 6, 2023
Phase: Phase 1
Study type: Interventional

This trial is conducted in China. The purpose of this study is to evaluate the pharmacokinetic similarity of Tafolecimab with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of sintilimab with different manufacturing process,also to determine Pharmacodynamics of Tafolecimab with different manufacturing process

NCT ID: NCT05768360 Completed - Clinical trials for Healthy Male Subjects

A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects

Start date: April 25, 2023
Phase: Phase 1
Study type: Interventional

This study will assess the effects of savolitinib on the pharmacokinetics (PK) of substrates of human transporters digoxin (P-gp), rosuvastatin (OATP1B1/3), metformin (OCT2, MATE1/2K), and furosemide (OAT1/3) in healthy male subjects, performed at a single clinical unit.

NCT ID: NCT05621447 Completed - Clinical trials for Healthy Male Subjects

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Start date: September 7, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of [14C]TAS-303 following oral single dose

NCT ID: NCT05559554 Not yet recruiting - Clinical trials for Healthy Male Subjects

A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

Start date: October 26, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetic similarity of AK104 with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of AK104 with different manufacturing process.

NCT ID: NCT05478109 Not yet recruiting - Clinical trials for Healthy Male Subjects

A Clinical Trial of XZP-3287 for Material Balance

Start date: August 2, 2022
Phase: Phase 1
Study type: Interventional

A single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of [14C] XZP-3287

NCT ID: NCT05446233 Completed - Clinical trials for Healthy Male Subjects

ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects

Start date: November 15, 2022
Phase: Phase 1
Study type: Interventional

This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of [14C] Antaitavir Hasophate.